Important notice

This document has been electronically translated using automated software. The original document is in German. This is a non-binding translation service. Only the German version is relevant. You can access the German version by changing the language settings to German.

Securities Information Sheet pursuant to § 4 of the German Securities Prospectus Act (Wertpapier-prospektgesetz)

Warning: The acquisition of this security is associated with considerable risks and can lead to the complete loss of the invested assets.

Status: 04.09.2019 - Number of updates: 0

1.	**Type, exact name and international securities identification number (ISIN) of the security** Type: Share pursuant to Article 4 paragraph 1 number 44 letter a of Directive 2014/65/EU in conjunction with § 2 number 1 of the German Securities Prospectus Act (WpPG), Article 2 letter a of Regulation (EU) 2017/1129 Exact designation: registered ordinary shares of 2C Dental AG ("2C Dental AG ordinary shares") International Securities Identification Number (ISIN): DE000A2YPJMM8
2.	**Functioning of the security including the rights attached to the security** - The share represents a *share in the company* (share in the issuer's share capital) and the *membership rights* attached to it in accordance with the legal provisions and the issuer's articles of association. By subscribing to the share, the investor becomes a shareholder of the issuer after the capital increase has been entered in the commercial register of the issuer. It shall participate in the issuer's share capital to the extent of the nominal value of the shares subscribed by it. The share capital of the issuer amounts to EUR 50,000.00 at the beginning of the issue and consists of 50,000 ordinary shares with a nominal value of EUR 1.00 each. It is increased in the course of the issue (capital increase) and the 7,936 new ordinary shares thus created (with a nominal value of EUR 1.00 each) are issued to the investors. The statutory subscription right of existing shareholders is excluded. By subscribing to the share, the investor receives, in particular, the right as a member to participate in the *distributed profits of* the issuer on a pro rata basis and to participate in any *liquidation proceeds*. The shares offered carry dividend rights from 1 January 2019. The profit shall be distributed evenly among the ordinary shares unless the general meeting of the issuer resolves otherwise. Pursuant to § 195 BGB, dividend claims expire after three years. Clearstream Banking AG, Frankfurt am Main, which deposits the global certificate for the new shares of the Company, will automatically credit the dividends attributable to the shares to the respective custodian banks. By subscribing to the ordinary share, the investor also receives a *voting right at the* issuer's Annual General Meeting. Each ordinary share carries one vote. In addition, various other rights are associated with the shares, in particular the right to subscribe to newly issued shares in the event of capital increases (Section 186 AktG), the right to contest resolutions of the Annual General Meeting (Section 246 No. 1-3 AktG), the right of the Executive Board to information on the affairs of the Company at the Annual General Meeting (Section 131 AktG) and, if applicable, various minority rights. Form, securitisation and trading venue of the shares: All shares of the issuer have been and will be securitised in one or more global certificates. The form of the share certificates shall be determined by the Management Board. The right of shareholders to individual securitization is excluded. The new shares will be deposited with Clearstream Banking AG, Frankfurt am Main, Mergenthalerallee 61, 65760 Eschborn, Germany. The Company's shares are traded over-the-counter. The shares are *registered shares with restricted transferability*, i.e. the shares can only be transferred with the consent of the issuer in accordance with Section 6.2 of the issuer's Articles of Association. The executive committee decides on the approval. The global certificate deposited with Clearstream Banking AG for the new shares which are the subject of the Offer will be provided with a blank endorse-ment and the Issuer generally consents to its transfer with the blank endorsement. The ordinary shares that are the subject of the Offer have the same rights as all other ordinary shares of the Issuer and do not confer any rights or benefits beyond those rights or benefits. In addition to subscribing to the shares, the investors conclude a *shareholder agreement*, a *voting and pooling agreement* and a *participation agree-ment as* part of a uniform offer. The conclusion of these three agreements is a prerequisite for subscribing to the share. The content of each of the three agreements is described in more detail below. The *shareholders' agreement* gives investors, as shareholders under certain conditions, *pre-emption and co-sale rights* if other shareholders of the issuer wish to sell their shares. A pre-emptive right exists if other shareholders wish to sell shares representing more than 10 percent of all shares or voting rights in the issuer. A co-sale right exists if other shareholders wish to sell shares representing more than 25 percent of all shares or voting rights in the issuer. In return, the shareholders' agreement obliges the investors to co-sell their shares under certain conditions.Such an *obligation to co-sell* exists in the event of a purchase offer by a third party to acquire more than 50 percent of all shares or voting rights in the issuer. In the event of a sale of more than 50 percent of all shares or voting rights of the Company, the investors are, under certain conditions, to participate in the proceeds of the sale with priority over other shareholders (*preferred disposal proceeds*). In addition, investors must participate in any surplus from any liquidation of the issuer with priority over other shareholders (*liquidation preference*). After the liquidation preference, the investors initially receive their investment amount repaid from the proceeds of the sale. Only the remaining proceeds from the sale will be distributed proportionately among the remaining shareholders and the investors. The amount paid out on the basis of the liquidation preference is credited against the investor's proportionate participation (simple creditable liquidation preference). In addition, they are protected against a "dilution" of their participation (i.e. against a reduction of their share in the Company) in the event of subsequent capital increases by the Company if shares are issued at a price per share of less than EUR 189.00 in a new capital increase within 24 months of the capital increase (*dilution protection*). In this case, the investors then have the opportunity to subscribe for as many additional shares at the issue price of EUR 1.00 as are necessary to place the investor as if he had purchased shares at an issue price that corresponds to the weighted arithmetic mean of the issue price in both capital increases. The shareholders' agreement has a minimum term of fifteen years. The *voting and pooling agreement* means that the investors together with other shareholders of the issuer form a voting pool. Under that agreement, the pool member submits to the *majority decisions* taken in that pool by undertaking to exercise its shareholder rights (in particular its voting rights) and other rights related to its shareholder status only in a manner consistent and uniform with the other pool members. The pool members decide on the matters subject to the voting and pooling agreement in an electronic procedure (*pool meeting*). The decisions of the pool meeting are imple-mented by Companisto Beteiligungs GmbH & Co. KG (pool leader) as decided by the pool meeting (without its own decision-making scope). To this extent, the investors authorize the pool leader in the agreement to exercise their shareholder rights. If shares of the pool members are sold as a result of the exercise of co-sale rights or co-sale obligations, the pool leader takes over the handling of the sale for the respective pool members. The voting and pooling agreement has a minimum term of fifteen years. Under the *Participation Agreement,* the investors undertake to make an additional payment to the capital reserves of the issuer of EUR 188.00 per acquired share in addition to the payment of the nominal amount of EUR 1.00 per share. The additional payment to the capital reserve cannot be reclaimed from the investor when the shares are sold. The total amount of the payment obligation per share thus amounts to EUR 189.00. The investor will participate in the issuer for each subscribed share with a nominal value of EUR 1.00 per share. Any personal liability on the part of investors in excess of the amount invested is excluded. Investors are not obliged to make additional contributions in excess of the amount invested.
3.	2C Dental AG ("Offerer" and "Issuer" **of** the **Security**), Edisonstraße 63, Aufgang E, 12459 Berlin, registered in the commercial register of the Charlottenburg Local Court under HRB 208313 B is a newly founded company and was founded on 18 June 2019**.** Business activity is die Erforschung, die Entwicklung, die industrielle Fertigung, die Vermarktung und der Vertrieb von Medical technologies, products and devices, especially in the dental field and related services, as well as the licensing and licensing of companies at home and abroad. The rights under the security are not secured by a guarantee.

4.	**The risks associated with the security and the issuer** **With this entrepreneurial investment, the investor enters into a long-term commitment. He should therefore include all relevant risks in his investment decision. In the following, not all but only the main risks associated with the investment can be listed.**
	Risks associated with the security:
	Maximum risk - There is a risk of total loss of the invested amount. By subscribing to the share, the investor provides the issuer with equity capital that is tied up indefinitely (i.e. is not subject to any repayment obligation). In a possible crisis of the issuer, equity serves as liable capital, i.e. it is used primarily to satisfy the claims of the issuer's creditors. The share is an entrepreneurial participation whose remuneration is purely performance-related (profit participation). The value of the issuer's shares may be subject to significant fluctuations. It is uncertain whether, when and to what extent profits will be distributed. Individually, the investor may suffer additional financial disadvantages. This may be the case, for example, if the investor is financing the acquisition of the security through a loan, if he has firmly planned proceeds from the security to cover other obligations despite the existing risk of loss, or due to costs for subsequent tax payments. In the worst case, such additional financial disadvantages can even lead to the private insolvency of the investor. The security is only suitable as an addition to an investment portfolio.
	Availability - There is currently no liquid secondary market for the shares. A sale of the shares by the investor is generally possible. However, the possibility of sale is not assured due to the small market size and trading activity. There is a risk that the investor will not find a buyer for his shares. The invested capital can therefore be permanently tied up.
	Risks associated with the issuer:
	Business risk of the issuer - Neither the economic success of the issuer's business activities nor the success of the planned implementation of the issuer's corporate strategy (see section 9 "Planned use of the expected net proceeds from the issue" below) can be predicted with certainty. The issuer cannot guarantee or warrant the amount and timing of inflows. Economic success depends on several factors, in particular the successful implementation of the corporate strategy within the planned budget; the implementation of the sales strategy; the development of the market in which the issuer is active (the market for orthodontics and orthodontic corrective measures). Various factors, such as the early market entry of competitors; the appearance of alternative products or technologies; delays, unexpected difficulties or cost overruns in the further development of the product range; changes in the legal, fiscal and/or political framework; interest rate and inflation developments and other aspects may have an adverse effect on the issuer. In addition, it will be crucial for the issuer's business success that marketing and distribution of the product can be successfully established and sales promises kept. The issuer must service senior debt regardless of its income situation. If the business risk materialises, there is a risk that the issuer will not be able to make distributions to the investor.
	Risks from increasing competition and progressive further developments - The issuer is in competition with other providers in its business field, some of whom are financially stronger and better known than the issuer. This competition could intensify significantly if more capital-rich competitors expand their businesses in the market in which the issuer is active. This could increase price pressure, reduce demand or otherwise adversely affect the issuer's business development. Furthermore, it cannot be ruled out that competitors may develop and offer products and services that are superior to those of the issuer and/or meet with greater market acceptance. In general, there is no guarantee that the issuer will be successful in the face of current and future increasing competition. There is then a risk that the issuer will not be able to make distributions to the investor.
	Risks from the early implementation phase of the business model - The issuer has made efforts to establish a new business area (the development and distribution of the 2Clear system), the further expansion of which will be financed by the issue. The issuer is currently not generating a positive operating cash flow in this business segment (i.e. the outflow of cash and cash equivalents from investing and operating activities exceeds the currently foreseeable inflow of cash and cash equivalents from operating activities). The issuer may therefore be dependent in the future - beyond the targeted volume of this financing - on acquiring further growth capital before this division can finance itself from its own sales. If the business idea is not successful in the market, if insufficient further growth capital cannot be raised or if the planned expansion of business cannot be implemented as hoped, investors are exposed to a total loss risk.
	Key person risk - In the event of a possible loss of the issuer's key personnel, there is a risk that expertise will no longer be available and that qualified business structure and risk management can therefore no longer be fully guaranteed. The loss of such persons could have an adverse effect on the economic development of the issuer. There is a risk that the issuer will then be unable to make fewer or no distributions to the investor.
	Forecast risk - The forecasts regarding the costs of implementing the corporate strategy, the achievable earnings and other aspects may prove to be inaccurate. Past market or business developments are no basis or indicator for future developments. If the forecasts turn out to be inaccurate, there is a risk that the issuer will then be able to make less or no distributions to the investor.
	Risk of limited shareholder rights - The investor can only subscribe to the shares offered if he also concludes the participation agreement, the shareholder agreement and the voting rights and pooling agreement. These have a minimum term of fifteen years. The shares may be sold earlier by the investor at any time. However, the purchaser of the shares is then obliged to enter into these agreements as legal successor. These agreements entail the risk that investors will only be able to exercise their shareholder rights in accordance and uniformity with the other shareholders. In the event of a majority decision in the pool meeting, the shareholder rights of the investor will be executed by the pool leader in accordance with the majority decision. There is a risk that a majority decision of the pool meeting may contradict the individual decision of the investor.
5.	**Debt-equity ratio of the issuer and of any guarantor -** The debt ratio of the issuer cannot be disclosed as it is a newly created company and annual accounts have not yet been prepared.
6.	**Prospects for capital repayment and returns under various market conditions** - The scenarios below are not exhaustive. There may also be other scenarios; for example, a possible insolvency of the issuer may lead to a total loss of the invested capital. The investor is not entitled to repayment of the invested capital, except in the event of the dissolution of the Company and provided that there is a sufficient liquidation surplus. The subscription of shares has an entrepreneurial and long-term character. This is an entrepreneurial participation that does not provide for a fixed interest rate, but exclusively for a performance-related profit participation. As a growth company, the issuer intends to give priority to reinvesting any surpluses generated in order to increase its enterprise value and therefore not to distribute any dividends in the foreseeable future. No earnings from rights from the share are to be expected in the coming years, either in the event of a positive, neutral or negative development. Investors may be able to make a profit from a subsequent sale of their shares if the issuer can increase its enterprise value in the meantime. The selling price to be achieved depends on the one hand on the economic development of the issuer itself, but on the other hand also on the general economic development and the associated development of the stock markets. The market primarily relevant for the issuer is the market for orthodontic corrective measures in the USA and Europe. Orthodontic products are predominantly used by orthodontists and general dentists to correct malocclusions in teenagers and adults. The issuer plans to generate sales primarily from the sale of the 2Clear System to orthodontists and general dentists. If the entrepreneurial strategy is successfully implemented in line with forecasts and the market environment is sufficiently stable (constant or rising demand for aesthetic and efficient orthodontic corrective measures, stable technological and competitive environment, unchanged legal framework conditions), the issuer will be able to increase its enterprise value as planned and later distribute profits. In the event of a negative development (falling demand for aesthetic and efficient orthodontic corrective measures, increased competition from Germany and abroad or unfavourably changed legal framework conditions), it is conceivable that the investor will receive less or no profits and/or will not be able to sell his shares at a profit. For the following scenario, it is assumed by way of example that the investor acquires 53 shares with a total nominal value of EUR 53.00 at a purchase price of EUR 10,017.00 (53 shares at an issue price of EUR 189.00 each) and sells them at a later date in the event of positive, neutral and negative developments on the stock markets, the general economic development and the economic development of the issuer. Flat-rate costs - e.g. for tax advisors and bank charges - amounting to 1% of the sale proceeds are assumed. Tax effects as well as possible dividend payments are not taken into account in the scenario presentation. The actual costs incurred by the investor may differ from the costs taken into account in the scenario analysis. Forecasts are not a reliable indicator of actual performance.

Scenario **(Forecast)**	expenses	disposal proceeds	Net amount (proceeds from sale less costs)	Investment result (proceeds from sale less investment amount)
In a positive scenario, the investor sells at 130% of the purchase price.	EUR 130.22	EUR 13,022.10	EUR 12,891.88	EUR 2,874.88
The investor sells 100% of the purchase price in a neutral scenario.	EUR 100.17	EUR 10,017.00	EUR 9,916.83	EUR -100.17
The investor sells at 70 % of the purchase price in a negative scenario	EUR 70.12	EUR 7,011.90	EUR 6.941,78	EUR -3,075.22

7. The costs and commissions associated with the security are as follows

Investors: Apart from the acquisition costs (payment amount per share, see section 8 "Offer conditions and issue volume" below), the investor does not incur any costs or commissions. Depending on the individual case, the investor may incur third-party costs in addition to the subscription amount in connection with the acquisition, management and sale of the security, such as custodian fees and administrative costs in the event of sale, gift or inheritance.

Issuer: Effecta GmbH, Florstadt ("liability umbrella"), receives from the issuer a brokerage commission of up to EUR 74,995.20 (5% of the brokered capital) plus any applicable statutory turnover tax. Effecta GmbH forwards the majority of the commission to its contractually bound agent Companisto Wertpapier GmbH. In addition, Companisto Holding GmbH ("IT service provider") receives an IT service fee of up to EUR 74,995.20 from the issuer for the technical handling of the financing round. The maximum issue costs that would be incurred by the issuer if the maximum issue volume were reached would thus amount to EUR 149,990.40 in relation to the ordinary shares offered, plus any applicable statutory value-added tax. These remunerations are financed by the amount invested.

8. Offer Conditions and Issue Volume

The total consideration that can be achieved for the offered ordinary shares amounts to EUR 1,499,904.00 (maximum issue volume of ordinary shares). From 10.09.2019 to 01.10.2019, the subscription of the shares will be offered exclusively via Companisto Wertpapier GmbH as the tied agent of the liability umbrella.

Each investor subscribes for at least six ordinary shares or more. The denomination is one share. In addition to subscribing to the shares, the investors conclude a shareholder agreement, a voting and pooling agreement and a participation agreement as part of a uniform offer. The conclusion of these three agreements is a prerequisite for the subscription of the share (see section 2 "Functioning of the security including the rights associated with the security" above).

The investor is obliged to pay the nominal amount of EUR 1.00 per subscribed share as well as an additional payment of EUR 188.00 per share to the capital reserves of the issuer. The total amount of the payment obligation per share is thus EUR 189.00. Since at least six ordinary shares must be subscribed, the minimum subscription amount is EUR 1,134.00. A total of 7,936 ordinary shares can thus be subscribed.

The security is aimed at speculative investors who, in exchange for possibly higher returns, run the risk of losing some or all of their invested capital and are able to cope with this loss. The investor should have a long-term investment horizon and should not attach importance to special capital protection against market risks.

The shares are expected to be booked into investors' custody accounts six weeks after the completion of the issue (expected 12.11.2019). The shares are subscribed for by the investor by filling out the relevant electronic subscription form on the website www.companisto-investments.de .

9. Planned use of the expected net proceeds of the issue

The issuer intends to use the net proceeds from the issue of ordinary shares of up to EUR 1,349,913.60 to implement an entrepreneurial strategy. The Issuer is active in the orthodontic market. He develops and distributes the 2Clear system. The 2Clear System is a patented product combination (set) and a procedure based on it, which corrects tooth misalignments by a two-stage treatment with fixed braces (1st treatment phase) and plastic splints (2nd treatment phase). The entrepreneurial strategy essentially provides for the following measures: Pre-production of 2Clear systems, product launch of the 2Clear system in the USA and Europe, marketing and sales of the product. The implementation of the measures now to be financed has already begun in part.

Information pursuant to § 4 (5) of the German Securities Prospectus Act (Wertpapierprospektgesetz)

The accuracy of the contents of the Securities Information Sheet is not subject to examination by the Federal Financial Supervisory Authority.

No securities prospectus approved by the Federal Financial Supervisory Authority has been filed for the security. The investor receives further information directly from the offeror or issuer of the security.

The issuer's annual accounts are not yet available, as this is a newly established company and annual accounts have not yet been prepared. In future, the issuer's annual financial statements will be available under the following link: www.bundesanzeiger.de .

Claims on the basis of an information contained in this Securities Information Sheet may only exist if the information is misleading or incorrect or if the warning in § 4 (4) WpPG is not contained and if the purchase transaction was concluded after publication of the Securities Information Sheet and for the duration of the public offering, but at the latest within six months after the first public offering of the securities in Germany.